Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$8.53−0.23 (-2.68%)
Close on Nov 13, 2026Market cap $1.41BP/E –Yield –
Novavax operating margin
Operating margin is operating income as a percentage of revenue.
Novavax's operating margin for the twelve months ending Sep 30, 2026 was -21.2%. For fiscal 2025 it was 40.3%, against -36.5% the year before. The highest annual figure on record is 40.3% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 40.3% | +76.8 |
| FY2024 | Dec 31, 2024 | -36.5% | +21.1 |
| FY2023 | Dec 31, 2023 | -57.6% | −25.1 |
| FY2022 | Dec 31, 2022 | -32.5% | +114.6 |
| FY2021 | Dec 31, 2021 | -147.1% | −59.5 |
| FY2020 | Dec 31, 2020 | -87.6% | +558.5 |
| FY2019 | Dec 31, 2019 | -646.1% | −138.9 |
| FY2018 | Dec 31, 2018 | -507.2% | +43.5 |
| FY2017 | Dec 31, 2017 | -550.8% | +1202.1 |
| FY2016 | Dec 31, 2016 | -1752.8% | −1319.1 |
| FY2015 | Dec 31, 2015 | -433.8% | −160.8 |
| FY2014 | Dec 31, 2014 | -273.0% | −22.3 |
| FY2013 | Dec 31, 2013 | -250.7% | −116.3 |
| FY2012 | Dec 31, 2012 | -134.4% | +12.5 |
| FY2011 | Dec 31, 2011 | -146.9% | +11075.8 |
| FY2010 | Dec 31, 2010 | -11222.7% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -45.8% | +206.9 |
| Q2 FY2026 | Jun 30, 2026 | -96.8% | −139.1 |
| Q1 FY2026 | Mar 31, 2026 | -11.1% | −88.4 |
| Q4 FY2025 | Dec 31, 2025 | 9.7% | +158.1 |
| Q3 FY2025 | Sep 30, 2025 | -252.7% | −94.1 |
| Q2 FY2025 | Jun 30, 2025 | 42.2% | +3.5 |
| Q1 FY2025 | Mar 31, 2025 | 77.3% | +231.6 |
| Q4 FY2024 | Dec 31, 2024 | -148.4% | −85.4 |
| Q3 FY2024 | Sep 30, 2024 | -158.6% | −91.4 |
| Q2 FY2024 | Jun 30, 2024 | 38.7% | +25.7 |
| Q1 FY2024 | Mar 31, 2024 | -154.3% | +232.1 |
| Q4 FY2023 | Dec 31, 2023 | -63.0% | +5.2 |
| Q3 FY2023 | Sep 30, 2023 | -67.2% | −49.9 |
| Q2 FY2023 | Jun 30, 2023 | 13.1% | +272.8 |
| Q1 FY2023 | Mar 31, 2023 | -386.4% | −416.1 |
| Q4 FY2022 | Dec 31, 2022 | -68.2% | +303.0 |
| Q3 FY2022 | Sep 30, 2022 | -17.3% | +154.4 |
| Q2 FY2022 | Jun 30, 2022 | -259.8% | −143.7 |
| Q1 FY2022 | Mar 31, 2022 | 29.7% | +76.4 |
| Q4 FY2021 | Dec 31, 2021 | -371.3% | −305.9 |
| Q3 FY2021 | Sep 30, 2021 | -171.7% | −48.2 |
| Q2 FY2021 | Jun 30, 2021 | -116.0% | −68.1 |
| Q1 FY2021 | Mar 31, 2021 | -46.6% | +631.4 |
| Q4 FY2020 | Dec 31, 2020 | -65.4% | +260.2 |
| Q3 FY2020 | Sep 30, 2020 | -123.5% | +474.3 |
| Q2 FY2020 | Jun 30, 2020 | -47.9% | +1044.3 |
| Q1 FY2020 | Mar 31, 2020 | -678.0% | +332.1 |
| Q4 FY2019 | Dec 31, 2019 | -325.6% | +433.5 |
| Q3 FY2019 | Sep 30, 2019 | -597.8% | −56.1 |
| Q2 FY2019 | Jun 30, 2019 | -1092.2% | −702.4 |
| Q1 FY2019 | Mar 31, 2019 | -1010.1% | −559.3 |
| Q4 FY2018 | Dec 31, 2018 | -759.1% | −300.2 |
| Q3 FY2018 | Sep 30, 2018 | -541.7% | −43.3 |
| Q2 FY2018 | Jun 30, 2018 | -389.8% | +226.2 |
| Q1 FY2018 | Mar 31, 2018 | -450.8% | +268.0 |
| Q4 FY2017 | Dec 31, 2017 | -458.9% | +542.1 |
| Q3 FY2017 | Sep 30, 2017 | -498.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -616.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -718.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -1001.0% | – |
See a number that looks wrong?